CU24631B1 - Método para inactivar xenoantígenos en tejidos biológicos - Google Patents

Método para inactivar xenoantígenos en tejidos biológicos

Info

Publication number
CU24631B1
CU24631B1 CU2018000048A CU20180048A CU24631B1 CU 24631 B1 CU24631 B1 CU 24631B1 CU 2018000048 A CU2018000048 A CU 2018000048A CU 20180048 A CU20180048 A CU 20180048A CU 24631 B1 CU24631 B1 CU 24631B1
Authority
CU
Cuba
Prior art keywords
xenoantigens
inactivate
biological tissues
tissues
hydroxytyrosol
Prior art date
Application number
CU2018000048A
Other languages
English (en)
Other versions
CU20180048A7 (es
Inventor
Alessandro Gandaglia
Filippo Naso
Original Assignee
Biocompatibility Innovation Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocompatibility Innovation Srl filed Critical Biocompatibility Innovation Srl
Publication of CU20180048A7 publication Critical patent/CU20180048A7/es
Publication of CU24631B1 publication Critical patent/CU24631B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3625—Vascular tissue, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Prostheses (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>La presente invención se refiere a un método para inactivar xenoantígenos en tejidos biológicos aislados del cuerpo humano, que comprende: proporcionar una solución de ácido cafeico, de ácido tánico o de hidroxitirosol, para la inactivación del epítopo alfa-Gal de dichos tejidos; incubar las muestras y someter los tejidos tratados a tres lavados.</p>
CU2018000048A 2015-11-30 2016-11-25 Método para inactivar xenoantígenos en tejidos biológicos CU24631B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITUB2015A006019A ITUB20156019A1 (it) 2015-11-30 2015-11-30 Metodo per l'inattivazione di xenoantigeni in tessuti biologici
PCT/EP2016/078898 WO2017093147A1 (en) 2015-11-30 2016-11-25 Method for inactivating xenoantigens in biological tissues

Publications (2)

Publication Number Publication Date
CU20180048A7 CU20180048A7 (es) 2018-11-06
CU24631B1 true CU24631B1 (es) 2022-12-12

Family

ID=55485194

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2018000048A CU24631B1 (es) 2015-11-30 2016-11-25 Método para inactivar xenoantígenos en tejidos biológicos

Country Status (18)

Country Link
US (1) US12589186B2 (es)
EP (1) EP3383446B1 (es)
JP (1) JP7169645B2 (es)
KR (1) KR20180090816A (es)
CN (1) CN108367098B (es)
AU (1) AU2016363536B2 (es)
BR (1) BR112018011021B1 (es)
CU (1) CU24631B1 (es)
DK (1) DK3383446T3 (es)
ES (1) ES2881603T3 (es)
IL (1) IL259591B (es)
IT (1) ITUB20156019A1 (es)
MX (1) MX385515B (es)
PL (1) PL3383446T3 (es)
RS (1) RS62100B1 (es)
RU (1) RU2754197C2 (es)
WO (1) WO2017093147A1 (es)
ZA (1) ZA201803786B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201600115523A1 (it) * 2016-11-16 2018-05-16 Biocompatibility Innovation Srl Metodo per l'inattivazione ed il controllo di avvenuta inattivazione di xenoantigeni in alimenti di origine animale, particolarmente per latte e derivati, e in alimenti di origine vegetale, particolarmente per succedanei di latte a base di soia e/o riso
WO2020234845A1 (en) 2019-05-22 2020-11-26 Biocompatibility Innovation Srl Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices
WO2024189407A1 (en) 2023-03-14 2024-09-19 Biocompatibility Innovation S.r.l. A method for imparting antimicrobial properties to a synthetic substrate
WO2025257595A1 (en) 2024-06-12 2025-12-18 Biocompatibility Innovation S.r.l. Preserving solution

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE408417T1 (de) * 2000-01-25 2008-10-15 Univ Nebraska Für die transplantation präparierte organe und abstossungsresistenz
US20040153145A1 (en) * 2002-11-26 2004-08-05 Clemson University Fixation method for bioprostheses
JP2007529278A (ja) * 2004-03-17 2007-10-25 レビビコア， インコーポレイテッド 機能的α１，３ガラクトシルトランスフェラーゼを欠く動物に由来する組織生成物
CA2627498C (en) * 2005-11-10 2013-06-11 Hill's Pet Nutrition, Inc. Compositions and methods for improving skin health and pelage quality
WO2007133479A2 (en) * 2006-05-10 2007-11-22 Cook Incorporated Delivery of elastin-stabilizing compound within a body lumen
CN101366979B (zh) * 2008-09-03 2012-08-29 陕西瑞盛生物科技有限公司 一种组织补片及其制备方法
FR2947456B1 (fr) * 2009-07-06 2012-03-09 Univ Bordeaux 1 Procede d'inactivation d'au moins un agent pathogene dans un echantillon de plasma sanguin humain
IL210162A0 (en) * 2010-12-21 2011-03-31 Omrix Biopharmaceuticals Viral inactivated platelet extract, use and preparation thereof
US9937255B2 (en) * 2011-05-18 2018-04-10 Nectero Medical, Inc. Coated balloons for blood vessel stabilization
RU2495928C2 (ru) * 2012-01-30 2013-10-20 Сергей Юрьевич Лешков Средство для стимуляции синтеза белков теплового шока hsp 70 в клетках человека и животных; косметическое средство для стимуляции репаративных процессов; косметическое средство для снижения побочных эффектов агрессивных косметологических процедур; биологически активная добавка; пищевой продукт; способ снижения побочных эффектов агрессивных косметологических процедур
ITPD20120029A1 (it) 2012-02-09 2013-08-10 Alessandro Gandaglia Metodo per la rilevazione di uno xenoantigene in tessuti fissati usati come sostituti bioprotesici
US9283241B2 (en) * 2012-07-10 2016-03-15 Clemson University Treatment to render implants resistant to diabetes
US9795573B2 (en) * 2013-09-24 2017-10-24 Clemson University Multi-step connective tissue stabilization method and stabilized tissue formed thereby
US11951078B2 (en) * 2019-05-22 2024-04-09 Biocompatibility Innovation S.r.l. Method for preventing the formation of calcified deposits and for inactivating xenoantigens in biological matrices

Also Published As

Publication number Publication date
US12589186B2 (en) 2026-03-31
AU2016363536B2 (en) 2021-04-01
BR112018011021B1 (pt) 2021-12-07
RU2018123621A (ru) 2020-01-09
RS62100B1 (sr) 2021-08-31
JP7169645B2 (ja) 2022-11-11
ITUB20156019A1 (it) 2017-05-30
CN108367098B (zh) 2021-06-11
AU2016363536A1 (en) 2018-06-28
IL259591A (en) 2018-07-31
EP3383446B1 (en) 2021-04-28
KR20180090816A (ko) 2018-08-13
US20180353647A1 (en) 2018-12-13
DK3383446T3 (da) 2021-07-26
BR112018011021A2 (pt) 2018-11-21
MX2018006577A (es) 2018-09-05
ES2881603T3 (es) 2021-11-30
IL259591B (en) 2022-04-01
WO2017093147A1 (en) 2017-06-08
CA3006234A1 (en) 2017-06-08
EP3383446A1 (en) 2018-10-10
JP2019503821A (ja) 2019-02-14
CN108367098A (zh) 2018-08-03
RU2018123621A3 (es) 2020-04-10
MX385515B (es) 2025-03-18
CU20180048A7 (es) 2018-11-06
PL3383446T3 (pl) 2021-11-02
RU2754197C2 (ru) 2021-08-30
ZA201803786B (en) 2019-02-27

Similar Documents

Publication Publication Date Title
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
DOP2017000186A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
EP3468356A4 (en) GENETICALLY MODIFIED CELLS, TISSUES AND ORGANS FOR THE TREATMENT OF DISEASES
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
CO6640274A2 (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
UY36458A (es) Anticuerpos humanos para hemaglutinina influenza.
CO2017000571A2 (es) Procedimiento de inactivación de inmunoglobulina endógena que permite facilitar procedimientos médicos que se ven afectados por la presencia de inmunoglobulina endógena
UY33047A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
BR112017022768A2 (pt) desinfecção de tecido com ondas de choque de pressão acústica
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX372723B (es) Métodos para marcar una molécula deuterada o no deuterada y formulaciones farmacéuticas para tratamiento.
IL257818A (en) Compositions and methods for multipurpose disinfection and sterilization solutions
GT201600084A (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso
CL2014000432A1 (es) Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica.
MX2017008277A (es) Solucion oftalmica acuosa.
BR112016026545A8 (pt) eribulina ou um sal farmaceuticamente aceitável do mesmo, seus usos e kit para utilização no tratamento de câncer da mama
JOP20190056B1 (ar) مركبات للاستخدام في علاج القصور الكلوي الحاد
BR112016028895A2 (pt) composições biofotônicas termofixas e usos destas
BR112018067967A2 (pt) tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante
MX2017008823A (es) Metodos para aislamiento de plaquetas.
MX2015016057A (es) Solucion estabilizada de acido hipocloroso y uso de la misma.
AR104598A1 (es) Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t
MX2018012230A (es) Métodos para tratar enfermedades oculares.
MX2019005979A (es) Peptidos modificados.